不知你用的疟疾药名字叫什么? 是医生开的处方药吗? 转一种药的介绍

令外，同样的药在不同的地方价格是不一样。比如新西兰的价格要比美国便宜好多。

 

Side Effects of Malarone - for the Consumer

Malarone

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Malarone:

Cough; diarrhea; dizziness; headache; loss of appetite; mouth sores; nausea; stomach pain; vomiting; weakness.

Seek medical attention right away if any of these SEVERE side effects occur when using Malarone:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest or throat; swelling of the mouth, face, lips, or tongue; unusual hoarseness); dark urine; fever, chills, or persistent sore throat; mood or mental changes; muscle or back pain; pale stools; red, blistered, swollen, or peeling skin; ringing in the ears; seizures; severe or persistent vomiting, diarrhea, or stomach pain; shortness of breath; unusual fatigue or weakness; weight loss; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

Top

Malarone Side Effects - for the Professional

Malarone

Because Malarone contains atovaquone and proguanil hydrochloride, the type and severity of adverse reactions associated with each of the compounds may be expected. The higher treatment doses of Malarone were less well tolerated than the lower prophylactic doses.

Among adults who received Malarone for treatment of malaria, attributable adverse experiences that occurred in ≥5% of patients were abdominal pain (17%), nausea (12%), vomiting (12%), headache (10%), diarrhea (8%), asthenia (8%), anorexia (5%), and dizziness (5%). Treatment was discontinued prematurely due to an adverse experience in 4 of 436 adults treated with Malarone.

Among pediatric patients (weighing 11 to 40 kg) who received Malarone for the treatment of malaria, attributable adverse experiences that occurred in ≥5% of patients were vomiting (10%) and pruritus (6%). Vomiting occurred in 43 of 319 (13%) pediatric patients who did not have symptomatic malaria but were given treatment doses of Malarone for 3 days in a clinical trial. The design of this clinical trial required that any patient who vomited be withdrawn from the trial. Among pediatric patients with symptomatic malaria treated with Malarone, treatment was discontinued prematurely due to an adverse experience in 1 of 116 (0.9%).

In a study of 100 pediatric patients (5 to <11 kg body weight) who received Malarone for the treatment of uncomplicated P. falciparum malaria, only diarrhea (6%) occurred in ≥5% of patients as an adverse experience attributable to Malarone. In 3 patients (3%), treatment was discontinued prematurely due to an adverse experience.

Abnormalities in laboratory tests reported in clinical trials were limited to elevations of transaminases in malaria patients being treated with Malarone. The frequency of these abnormalities varied substantially across studies of treatment and were not observed in the randomized portions of the prophylaxis trials.

In one phase III trial of malaria treatment in Thai adults, early elevations of ALT and AST were observed to occur more frequently in patients treated with Malarone compared to patients treated with an active control drug. Rates for patients who had normal baseline levels of these clinical laboratory parameters were: Day 7: ALT 26.7% vs. 15.6%; AST 16.9% vs. 8.6%. By day 14 of this 28-day study, the frequency of transaminase elevations equalized across the 2 groups.

In this and other studies in which transaminase elevations occurred, they were noted to persist for up to 4 weeks following treatment with Malarone for malaria. None were associated with untoward clinical events.

Among subjects who received Malarone for prophylaxis of malaria in placebo-controlled trials, adverse experiences occurred in similar proportions of subjects receiving Malarone or placebo (Table 3). The most commonly reported adverse experiences possibly attributable to Malarone or placebo were headache and abdominal pain. Prophylaxis with Malarone was discontinued prematurely due to a treatment-related adverse experience in 3 of 381 adults and 0 of 125 pediatric patients.

所有跟帖： 

• 我上面typo，就是医生开的Malarone -tang07059- ♂ (142 bytes) () 10/23/2011 postreply 13:51:21